This legislation, known as the Medicare IVIG Access Enhancement Act of 2025, aims to significantly expand Medicare coverage for the in-home administration of intravenous immune globulin (IVIG), which is currently covered for primary immune deficiency diseases. Beginning January 1, 2027, this bill proposes to extend that coverage to include patients suffering from chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) , thereby broadening access to this critical treatment. Additionally, the bill grants the Secretary of Health and Human Services the authority to establish varied payment rates for the in-home administration of IVIG. These payment variations could depend on whether the treatment is for primary immune deficiency diseases or for the newly covered conditions of CIDP and MMN, with such determinations made through a notice and comment rulemaking process.